Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplements and pre-eclampsia

This article was originally published in The Tan Sheet

Executive Summary

"Concomitant supplementation with vitamin C and vitamin E does not prevent pre-eclampsia in women at high risk, but does increase the rate of babies born with a low birthweight," according to a study published online by The Lancet March 30. The randomized, placebo-controlled trial enrolled 2,410 women identified as at increased risk of pre-eclampsia and who were assigned either 1,000 mg vitamin C and 400 IU vitamin E daily or placebo. Pre-eclampsia rates did not differ between the treatment group (15%) and placebo (16%), but more low birthweight babies were born to those treated than those on placebo (28% versus 4%). "As such, use of these high-dose antioxidants is not justified in pregnancy," Lucilla Poston, St. Thomas' Hospital, London, et al., conclude. "The daily doses of vitamin C and vitamin E that we gave were below the maximum recommended intake in pregnant women," they note...

You may also be interested in...

Naturopath Marketing Brain Defense Supplement Anticipates Support For Making TBI Claims

Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.

Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients

The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.

Bayer Gives Consumer Health A Star, But Plans $1.76Bn In Annual Overall Cost Reductions

Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts